Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs

Oxyntomodulin (Gcgr-/- Vs Glp1r-/- Dissection)

MARKETED

GLP-1/glucagon dual agonist

1
graded findings
1
effect domains
Evidence spread
High evidence 0Moderate evidence 0Low evidence 0Very low evidence 1

Oxyntomodulin (Gcgr-/- Vs Glp1r-/- Dissection) is shown as a marketed evidence record where applicable. Findings describe observed research and regulatory records; they do not provide treatment advice.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Oxyntomodulin (Gcgr-/- Vs Glp1r-/- Dissection) MARKETED
Appetite and food intake No change
Very low evidence

In mice, oxyntomodulin's acute food-intake suppression is mediated through the GLP-1 receptor, NOT the glucagon receptor: anorexia preserved in Gcgr-/- but abolished...

Baggio LL, Huang Q, Brown TJ, Drucker DJ, Gastroenterology 2004;127(2):546-558 Source
Full findingIn mice, oxyntomodulin's acute food-intake suppression is mediated through the GLP-1 receptor, NOT the glucagon receptor: anorexia preserved in Gcgr-/- but abolished in Glp1r-/-; only exendin-4 (not OXM) additionally reduced VO2/RQ, dissociating the intake effect (GLP-1R) from energy expenditure.
PopulationMice (receptor knockouts)
Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)
Scope limitsReused from corpus T9-GCGR-07. Negative/isolating-OUT for GCGR: GCGR arm does NOT carry the dual-agonist acute satiety. Mouse genetic KO; species caveat.
Comparatorsvehicle; exendin-4